Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.

A Oliver SartorDaniel HeinrichNeil MariadosMaria José Méndez VidalDaniel KeizmanCamilla Thellenberg KarlssonAvivit PeerGiuseppe ProcopioStephen J FrankKalevi PulkkanenEli RosenbaumStefano SeveriJosé TrigoLucia TrandafirVolker WagnerRui LiLuke T Nordquist

Published in: The Prostate (2019)

Re-treatment with radium-223 in this selected patient population was well tolerated, led to minimal hematologic toxicity, and provided continued disease control in bone at 2-year follow-up.

Keyphrases

open label
clinical trial
radiation therapy
bone mineral density
body composition
study protocol
phase ii study
replacement therapy
soft tissue
oxide nanoparticles